Pacific Health reports results

Related tags Cent increase Revenue

Pacific Health Laboratories reports year end results and 79 per
cent increase in sales

PacificHealth Laboratories reported a net income of $285,627 (€323,836) , or $0.05 per share, for the year ended December 31, 2001 and revenues of $6,145,525, (€6.97m)compared to a net loss of ($957,566), or ($0.21) per share, for the same period in 2000.

The company said that it achieved a 79 per cent increase in sales of its sports drink products. This included new products, Accelerade, launched in June, and the EnduroxR4 sports drinks range.

The company also signed a licensing agreement with GlaxoSmithKline in June for its Satietrol technology, receiving a $1 million initial licensing fee and $250,000 in additional achievement payments during the year ended December 31, 2001.

The company reported that at year-end 2001, it had a working capital of $4.5 million compared to $1.6 million at year-end 2000 and had no long-term debt. It has also expanded its sales staff.

Dr. Robert Portman, president and CEO of Pacific Health, said: "This was a pivotal year for PacificHealth Laboratories. In 2001, we established the foundation for significant sales and revenue growth for 2002 and beyond."

Related topics Suppliers

Related news

Follow us

Products

View more

Webinars